Regression of liver cell adenoma

Bühler, H; Pirovino, M; Akovbiantz, A; Altorfer, J; Weitzel, Magdalena; Maranta, E; Schmid, Martin

doi:10.1016/0016-5085(82)90327-4

Cited by 85 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The etiological role of oral contraceptives in inducing liver cell adenoma is beyond doubt, and many studies have shown regression and even complete resolution of adenomas after cessation of the oral contraceptive pill [90–97]. This observation is not consistent, as others have not noted any change in the size of existing liver cell adenomas after discontinuation of oral contraceptives [98, 99].…”

Section: Complications and Management Of Solitary Liver Cell Adenomamentioning

confidence: 99%

Liver cell adenoma and liver cell adenomatosis

Barthelmes

Tait

2005

HPB

117

151

View full text Add to dashboard Cite

During the last three decades liver cell adenoma and liver cell adenomatosis have emerged as new clinical entities in hepato-logical practice due to the widespread use of oral contraceptives and increased imaging of the liver. On review of published series there is evidence that 10% of liver cell adenomas progress to hepatocellular carcinoma, diagnosis is best made by open or laparoscopic excision biopsy, and the preferred treatment modality is resection of the liver cell adenoma to prevent bleeding and malignant transformation. In liver cell adenomatosis, the association with oral contraceptive use is not as high as in solitary liver cell adenomas. The risk of malignant transformation is not increased compared with solitary liver cell adenomas. Treatment consists of close monitoring and imaging, resection of superficially located, large (>4 cm) or growing liver cell adenomas. Liver transplantation is the last resort in case of substantive concern about malignant transformation or for large, painful adenomas in liver cell adenomatosis after treatment attempts by liver resection.

show abstract

Section: Complications and Management Of Solitary Liver Cell Adenomamentioning

confidence: 99%

Liver cell adenoma and liver cell adenomatosis

Barthelmes

Tait

2005

HPB

117

151

View full text Add to dashboard Cite

show abstract

“…Sex, hormones, and genetic predisposition play an important role in the development of HCA 1–4 . Approximately 85% of HCA cases occur in young to middle-aged women with a history of oral contraceptive use 5,6 . Hepatocellular adenoma occasionally happens in men, in association with the use of anabolic steroids in some cases 7–9 .…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4] Approximately 85% of HCA cases occur in young to middle-aged women with a history of oral contraceptive use. 5,6 Hepatocellular adenoma occasionally happens in men, in association with the use of anabolic steroids in some cases. [7][8][9] It is relatively rare in children.…”

Section: General Clinical Characteristics and Risk Factors Of Hcamentioning

confidence: 99%

Hepatocellular Adenoma: A Case Report, Current Updates on Subtyping, and Diagnostic Pitfalls

Jung¹,

Liu²

2022

AJSP: Reviews and Reports

View full text Add to dashboard Cite

Hepatocellular adenoma (HCA) is a benign liver neoplasm that typically arises in the noncirrhotic liver. Based on molecular findings, HCA can be subclassified into the following subtypes: hepatocyte nuclear factor 1α-inactivated HCA, inflammatory HCA, β-catenin-activated HCA, sonic hedgehog-activated HCA, and unclassified HCA. Mixed β-cateninactivated inflammatory HCA may rarely occur. We report a case of HCA that was initially diagnosed as inflammatory HCA on a biopsy but finally was confirmed to be β-catenin-activated inflammatory HCA on the resection specimen. Most recent updates on molecular classification, key histologic features of each subtype, and common diagnostic pitfalls are discussed.

show abstract

“…Females taking OCPs have an incidence of 3-4 per 100,000 users compared with 0.13-1.0 per 100,000 in nonusers, with modern-era OCPs having markedly decreased concentration of estrogen and progesterone compared with the 1960s (27)(28)(29). Discontinuation of OCPs or estrogen-impregnated intrauterine devices has been associated with regression of adenomas in many cases (30,31).…”

Section: Hepatocellular Adenomamentioning

confidence: 99%

“…These are far less commonly associated with complications of hemorrhage and/or malignancy (63). The use of exogenous hormonal therapy should be discontinued (30,31). In the case of an elevated body mass index, weight loss should be encouraged, although there is no specific established weight loss target for adenoma regression (33,48).…”

Section: Key Conceptsmentioning

confidence: 99%

ACG Clinical Guideline: Focal Liver Lesions

Frenette,

Mendiratta-Lala,

Salgia

et al. 2024

Am J Gastroenterol

View full text Add to dashboard Cite

Focal liver lesions (FLLs) have become an increasingly common finding on abdominal imaging, especially asymptomatic and incidental liver lesions. Gastroenterologists and hepatologists often see these patients in consultation and make recommendations for management of multiple types of liver lesions, including hepatocellular adenoma, focal nodular hyperplasia, hemangioma, and hepatic cystic lesions including polycystic liver disease. Malignancy is important to consider in the differential diagnosis of FLLs, and healthcare providers must be familiar with the diagnosis and management of FLLs. This American College of Gastroenterology practice guideline uses the best evidence available to make diagnosis and management recommendations for the most common FLLs.

show abstract

Regression of liver cell adenoma

Cited by 85 publications

References 22 publications

Liver cell adenoma and liver cell adenomatosis

Liver cell adenoma and liver cell adenomatosis

Hepatocellular Adenoma: A Case Report, Current Updates on Subtyping, and Diagnostic Pitfalls

ACG Clinical Guideline: Focal Liver Lesions

Contact Info

Product

Resources

About